Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes the SWITCH 1 randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 1, 2017, Pages 33-44

  Lane, Wendy ^a   Bailey, Timothy S ^b   Gerety, Gregg ^c   Gumprecht, Janusz ^d   Philis Tsimikas, Athena ^e   Hansen, Charlotte Thim ^f   Nielsen, Thor S S ^f   Warren, Mark ^g,h  

^a Mountain Diabetes and Endocrine Center   (United States)

^b AMCR Institute   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e Whittier Institute for Diabetes   (United States)

^f NOVO NORDISK A S   (Denmark)

^g Physician's East PA   (United States)

^h School of Osteopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; TREATMENT DURATION; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; MULTICENTER STUDY;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85021813239     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.7115     Document Type: Article

References (28)

1. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711-722.
2. Leiter LA, Yale J-F, Chiasson J-L, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005; 29(3):186-192.
3. Nathan DM, Genuth S, Lachin J, et al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
4. Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16.
5. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6): 1614-1620.
6. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): A prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2(7):553-561.
7. Agesen RM, Kristensen PL, Beck-Nielsen H, et al. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial. DiabetesMetab. 2016;42(4):249-255.
8. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-Acting basal insulin. Pharm Res. 2012;29(8):2104-2114.
9. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes ObesMetab. 2012;14(9):859-864.
10. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-Acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944-950.
11. Novo Nordisk Co Announcement. Tresiba demonstrated lower day-To-day and within-day variability in glucose-lowering effect compared with insulin glargine U300. http://www.novonordisk .com/media/news-details.2056385.html. Posted November 16, 2016. Accessed January 6, 2017.
12. Heller S, Buse J, Fisher M, et al; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-To-Target non-inferiority trial. Lancet. 2012;379(9825):1489-1497.
13. Bode BW, Buse JB, Fisher M, et al; BEGIN Basal-Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013;30(11):1293-1297.
14. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-Analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175-184.
15. World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
16. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice 01 May 1996. https://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed January 6, 2017.
17. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36 (5):1384-1395.
18. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes AssociationWorkgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249.
19. Khunti K, Alsifri S, Aronson R, et al; HAT Investigator Group. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-Treated type 1 and type 2 diabetes: The global HAT study. Diabetes Obes Metab. 2016;18(9): 907-915.
20. Monami M, Marchionni N, Mannucci E. Long-Acting insulin analogues vs NPH human insulin in type 1 diabetes: Ameta-Analysis. Diabetes Obes Metab. 2009;11(4):372-378.
21. Chow E, Bernjak A, Williams S, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014;63(5):1738-1747.
22. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-Analysis with bias analysis. BMJ. 2013;347:f4533.
23. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897-1901.
24. Zoungas S, Patel A, Chalmers J, et al; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363(15):1410-1418.
25. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
26. Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17(3):176-183.
27. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes AssociationWorkgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-1249.
28. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care. 2017; 40(suppl 1):S1-S133.